Allylestrenol (BioDeep_00000014672)

 

Secondary id: BioDeep_00000858450

human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds


代谢物信息卡片


(1S,2R,10R,11S,14R,15S)-15-methyl-14-(prop-2-en-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-ol

化学式: C21H32O (300.24530219999997)
中文名称: 烯丙雌醇
谱图信息: 最多检出来源 Homo sapiens(lipidomics) 1.36%

分子结构信息

SMILES: C1CC=C2CC[C@@]3([H])[C@]4([H])CC[C@](CC=C)(O)[C@@]4(C)CC[C@]3([H])[C@]2(C1)[H]
InChI: InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1

描述信息

Allylestrenol is only found in individuals that have used or taken this drug. It is a synthetic steroid with progestational activity. [PubChem]Allylestrenol is similar in structure and function to progesterone. Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DC - Estren derivatives
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D011372 - Progestins
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
Same as: D01374

同义名列表

12 个代谢物同义名

(1S,2R,10R,11S,14R,15S)-15-methyl-14-(prop-2-en-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-ol; 19-norpregn-4-ene-20-yn-17beta-ol; Organon brand OF allylestrenol; Allylestrenol organon brand; Allyloestrenol; Allylestrenol; ST 21:2;O; Gestanin; Perselin; Gestanon; Turinal; Allylestrenol



数据库引用编号

17 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Xiaopeng Shi, Yin Wu, Taijun Hang, Xiaofeng Xu, Likun Ding, Yun Tian, Aidong Wen. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to a pharmacokinetic study of allylestrenol in healthy Chinese female volunteers. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Aug; 871(1):90-4. doi: 10.1016/j.jchromb.2008.06.054. [PMID: 18639502]
  • Kazumi Noguchi, Kotaro Suzuki, Jun-ichi Teranishi, Keiichi Kondo, Takeshi Kishida, Kazuo Saito, Hiroji Uemura, Yoshinobu Kubota. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. Hinyokika kiyo. Acta urologica Japonica. 2006 Jul; 52(7):527-30. doi: NULL. [PMID: 16910584]
  • Kazumi Noguchi, Mitsumasa Takeda, Masahiko Hosaka, Yoshinobu Kubota. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]. Hinyokika kiyo. Acta urologica Japonica. 2002 May; 48(5):269-73. doi: NULL. [PMID: 12094708]
  • K Noguchi, H Uemura, M Takeda, Y Sekiguchi, K Ogawa, M Hosaka. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia]. Hinyokika kiyo. Acta urologica Japonica. 2000 Sep; 46(9):605-7. doi: NULL. [PMID: 11107528]
  • K Noguchi, M Harada, M Masuda, M Takeda, Y Kinoshita, S Fukushima, K Miyai, H Fukuoka, M Hosaka. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy. International journal of urology : official journal of the Japanese Urological Association. 1998 Sep; 5(5):466-70. doi: 10.1111/j.1442-2042.1998.tb00389.x. [PMID: 9781436]
  • N Yasuda, K Fujino, T Shiraji, F Nambu, K Kondo. Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Japanese journal of pharmacology. 1997 Jul; 74(3):243-52. doi: 10.1254/jjp.74.243. [PMID: 9268084]
  • E Pap, G Csaba. Effect of prenatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone level in adult rats. General pharmacology. 1995 Mar; 26(2):365-7. doi: 10.1016/0306-3623(94)00188-s. [PMID: 7590089]
  • E Pap, G Csaba. Effect of neonatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone concentration in adult rat. Reproduction, fertility, and development. 1995; 7(5):1249-51. doi: 10.1071/rd9951249. [PMID: 8848596]
  • E Pap, G Csaba. Benzpyrene treatment in adulthood increases the testosterone level in neonatally steroid(allylestrenol)-treated male rats. General pharmacology. 1994 Dec; 25(8):1699-701. doi: 10.1016/0306-3623(94)90374-3. [PMID: 7721048]
  • H Iguchi, T Ikeuchi, Y Kai, H Yoshida. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism]. Hinyokika kiyo. Acta urologica Japonica. 1994 Mar; 40(3):215-9. doi: NULL. [PMID: 7513937]
  • N Watanabe, S Yamada, Y Ishikawa, M Yokoyama. Reduction of plasma lipoprotein(a) by allylestrenol. Atherosclerosis. 1993 Sep; 102(2):229-30. doi: 10.1016/0021-9150(93)90166-r. [PMID: 8251010]
  • H Fukuoka, Y Ishibashi, T Shiba, F Tuchiya, S Sakanishi. [Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]. Hinyokika kiyo. Acta urologica Japonica. 1993 Jul; 39(7):679-83. doi: NULL. [PMID: 7689782]
  • A Barták, M Rozprávka, J Blovský. [Lynestrenol and allylestrenol in the therapy of postmenopausal hot flushes]. Ceskoslovenska gynekologie. 1992 Oct; 57(8):408-13. doi: . [PMID: 1473164]
  • Y Tsuji, A Ariyoshi, H Nakamura, S Michinaga, Y Tomita, A Ohmori, H Tahara, Y Yamashita, Y Fujisawa, I Kajiwara. [Antiandrogen therapy of benign prostatic hypertrophy: clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement]. Hinyokika kiyo. Acta urologica Japonica. 1992 Aug; 38(8):961-6. doi: NULL. [PMID: 1384295]
  • L Solti, K Eulenberger, D Kurth, L Schöne. Treatment of anoestrous mares with a synthetic progestagen, allyloestrenol. Acta veterinaria Hungarica. 1990; 38(3):177-85. doi: NULL. [PMID: 2099603]
  • A Birkenfeld, D Navot, Y Ezra, A Ron, J G Schenker. The effect of estradiol valerate and allylestrenol on endometrial transformation in hypergonadotropic hypogonadic women. European journal of obstetrics, gynecology, and reproductive biology. 1987 Jul; 25(3):221-9. doi: 10.1016/0028-2243(87)90102-x. [PMID: 3609436]
  • T Kaneoka, S Taguchi, H Shimizu, K Shirakawa. [Prenatal diagnosis and treatment of intrauterine growth retardation]. Nihon Sanka Fujinka Gakkai zasshi. 1986 Apr; 38(4):561-9. doi: NULL. [PMID: 3701145]
  • M Ohyama, T Tanifuji, C Haraguchi, N Fujii, Y Higaki, H Yoshida, K Imamura. [Clinical study of allylestrenol (Org AL-25) on patients with prostatic hypertrophy--transrectal ultrasonography and urodynamic examination]. Hinyokika kiyo. Acta urologica Japonica. 1986 Apr; 32(4):649-59. doi: NULL. [PMID: 2426933]
  • I Gerhard, B Runnebaum. Hormone load tests in the first half of pregnancy--a diagnostic and therapeutic approach. Biological research in pregnancy and perinatology. 1984; 5(4):157-73. doi: . [PMID: 6084523]
  • H Yamanaka, N Kosaku, T Makino, K Shida. [Fundamental and clinical study of the anti-prostatic effect of allylestrenol]. Hinyokika kiyo. Acta urologica Japonica. 1983 Sep; 29(9):1133-45. doi: NULL. [PMID: 6203385]
  • N G Kosheleva, F A Svechnikova, S B Golumb. [Use of turinal in the combined treatment of threatened abortion and its effect on placental hormone function]. Akusherstvo i ginekologiia. 1981 May; ?(5):23-5. doi: NULL. [PMID: 7306358]
  • J Cortés-Prieto, A O Bosch, J A Rocha. Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor. Clinical therapeutics. 1980; 3(3):200-8. doi: NULL. [PMID: 7459930]
  • J Spona, E Müller-Tyl, S Leodolter. [Influence of allylestrenol on hpl serum levels in high-risk pregnancies (author's transl)]. Zeitschrift fur Geburtshilfe und Perinatologie. 1976 Oct; 180(5):356-62. doi: NULL. [PMID: 969796]
  • F Tibor, B Lajos. [Determination of synthetic gestagenic hormones by gas chromatography]. Acta pharmaceutica Hungarica. 1976 Mar; 46(2):73-7. doi: NULL. [PMID: 1258655]
  • I BRADFORD, R GOMEZ ROJAS, E GARAY, J PERALES, G GENERINI. [EFFECTS OF ALLYLESTRENOL ON THE RENAL EXCRETION OF SODIUM, POTASSIUM AND WATER IN NORMAL SUBJECTS]. Revista medica de Chile. 1964 Jul; 92(?):530-2. doi: NULL. [PMID: 14223381]